Bevacizumab, an anti–vascular endothelial growth factor treatment for which 1 biosimilar has been approved to date, has been shown to improve quality of life for patients with glioblastoma—and to delay disease progression—but has not prolonged patients’ overall survival. However, recent research suggests that using 4 older drugs together with bevacizumab could provide a more effective treatment protocol.
Bevacizumab, an anti—vascular endothelial growth factor (anti-VEGF) treatment for which 1 biosimilar has been approved to date, has been shown to improve quality of life for patients with glioblastoma—and to delay disease progression—but has not prolonged patients’ overall survival.
However, recent research suggests that using 4 older drugs together with bevacizumab could provide a more effective treatment protocol. Writing in Medical Sciences, Richard E. Kast, MD, describes the current research supporting this regimen.
The drugs in question are apremilast, which treats psoriasis; dapsone, an antibiotic that treats Hansen disease; zonisamide, which treats seizures; and telmisartan, which treats hypertension.
Using these drugs in combination with bevacizumab is expected to lower intracranial pressure, allow for steroid-sparing treatment, enhance bevacizumab’s effects, provide synergy with temozolomide, exert anti-glioma effects, and have low risk of adverse events.
All of these drugs, writes Kast, are low-risk drugs when they are used individually, and are all relatively inexpensive and widely available. Phase 3 testing of the regimen will be necessary prior to general use, however.
Reference
Kast RE. Paths for improving bevacizumab available in 2018: the ADZT regimen for better glioblastoma treatment. Med Sci. 2018;6(4); 84. doi:10.3390/medsci6040084.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.